Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Treatment Outcome
100%
United States
100%
Treatment Patterns
100%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
100%
Chemoimmunotherapy
100%
Real-world Cohort
100%
Overall Survival
37%
Distant Metastasis
25%
Comorbidity
25%
Atezolizumab
25%
Durvalumab
25%
Risk Factors
12%
Older Patients
12%
Multivariable
12%
Treatment Options
12%
Liver
12%
Standard of Care
12%
Progression-free Survival
12%
Chronic Obstructive Pulmonary Disease
12%
Old Age
12%
Cox Proportional Hazards Model
12%
Increased Mortality
12%
Sufficient Follow-up
12%
Effective Treatment
12%
Kaplan-Meier Estimator
12%
Second-line Treatment
12%
Adrenal Gland
12%
Male Sex
12%
Rapid Disease Progression
12%
Online Treatment
12%
Claims Database
12%
Komodo
12%
Subsequent Therapy
12%
Line of Therapy
12%
Mortality Risk Factors
12%
Real-world Clinical Practice
12%
Nursing and Health Professions
Small Cell Lung Cancer
100%
Overall Survival
60%
Comorbidity
40%
Distant Metastasis
40%
Atezolizumab
40%
Durvalumab
40%
Proportional Hazards Model
20%
Kaplan Meier Method
20%
Progression Free Survival
20%
Clinical Practice
20%
Disease Exacerbation
20%
Obstructive Lung Disease
20%
Health Care Quality
20%
Cardiovascular System
20%
Real-World Evidence
20%
Medicine and Dentistry
Small Cell Lung Cancer
100%
Chemoimmunotherapy
100%
Overall Survival
37%
Distant Metastasis
25%
Comorbidity
25%
Atezolizumab
25%
Durvalumab
25%
Retrospective Study
12%
Proportional Hazards Model
12%
Kaplan Meier Method
12%
Progression Free Survival
12%
Chronic Obstructive Pulmonary Disease
12%
Disease Exacerbation
12%
Identified Patient
12%
Cardiovascular System
12%
Adrenal Gland
12%
Treatment Option
12%
Real-World Evidence
12%
Median Follow Up
12%
Effective Treatment
12%
Pharmacology, Toxicology and Pharmaceutical Science
Small Cell Lung Cancer
100%
Overall Survival
60%
Comorbidity
40%
Distant Metastasis
40%
Atezolizumab
40%
Durvalumab
40%
Retrospective Study
20%
Progression Free Survival
20%
Disease Exacerbation
20%
Chronic Obstructive Lung Disease
20%
Immunology and Microbiology
Lung
100%
Overall Survival
60%
Comorbidity
40%
Atezolizumab
40%
Durvalumab
40%
Cardiovascular System
20%
Progression Free Survival
20%
Adrenal Gland
20%